A caracterização fenotípica de Plasmodium falciparum permite conhecer o padrão de sensibilidade do parasito às drogas antimaláricas utilizadas em países endêmicos. No presente estudo avaliamos fenotipicamente isolados clínicos de P. falciparum provenientes do Continente Africano e do Caribe. A sensibilidade à dihidroartemisinina (DHA: 4 - 1.000 nM), artesunato (AS: 0,1 - 100 nM), lumefantrina (LMF: 3,1 - 200 nM) e mefloquina (MFQ: 0,2 - 1.000 nM) foi investigada por meio de quatro técnicas: (a) ensaio de sensibilidade ex-vivo e in vitro, (b) ensaio de dormência, (c) ensaio de citometria de fluxo e (d) ensaio de sobrevivência do trofozoíto jovem (Ring Stage Survival Assay - RSA). Nos experimentos ex-vivo e in vitro, os IC50 estabelecidos foram 0,4 - 66,6 nM para DHA; 3,8 - 48,8 nM para LMF; 0,3 - 25,9 nM para AS e 2 - 439 nM para MFQ. No ensaio de dormência, esquizontes foram observados na amostra de referência NF54 de P. falciparum e na amostra clínica S-01/15 após pressão com 62,5 nM, 250 nM e 1.000 nM de DHA. O período de recuperação variou de 4 a 40 dias. Para LMF, houve maturação para o estágio de esquizonte no isolado de referência no sétimo e décimo segundo dia após a exposição a 66,6 nM e 200 nM da droga, respectivamente. Esquizontes foram visualizados no isolado clínico FS-08/15 de P. falciparum depois da pressão com 100 nM de AS, com recuperação de 0 a 28 dias, portanto sem apresentar dormência. Na citometria de fluxo, trofozoítos jovens viáveis de P. falciparum marcados com Rodamina 123 e DAPI foram observados nas máximas concentrações de DHA (1.000 nM) e LMF (200 nM). Finalmente no RSA, a taxa de crescimento (TC) e porcentagem de supervivência (PS) do isolado de referência foi 2,92 e 4,19%, respectivamente, frente a 700 nM de DHA. O mesmo isolado pressionado com 3.500 nM de LMF apresentou 3,6 de TC e 2,25% de PS. A avaliação microscópica dos ensaios de sensibilidade ex-vivo e in vitro subestima a resposta de P. falciparum à terapia combinada com artemisinina (ACT). Nossos resultados sugerem que a dormência, principal mecanismo de tolerância às artemisininas (ART), não aconteceria em todos os isolados clínicos de P. falciparum. A citometria de fluxo avaliou com acurácia a viabilidade parasitária. No presente estudo, pela primeira vez foi reportada a dormência de P. falciparum à LMF / The phenotypic characterization of Plasmodium falciparum is useful for the knowledge of parasite sensitivity against antimalarial used in endemic countries. In this study we evaluated the sensitivity of clinical isolates of P. falciparum from the African continent and the Caribbean. The sensitivity to dihydroartemisinin (DHA: 4 - 1,000nM), artesunate (AS: 0.1 - 100 nM), lumefantrine (LMF: 3.1 to 200 nM), and mefloquine (MFQ: 0.2 to 1,000 nM) was investigated through four techniques: (a) ex vivo and in vitro microtests, (b) dormancy assay, (c) flow cytometry assay and (d) survival assay using young trophozoites (Ring Stage Survival Assay - RSA). In the ex vivo and in vitro experiments, the IC50 was calculated and was 0.4 - 66.6 nM for DHA; 3.8 - 48.8 nM for LMF; 0.3 - 25.9 nM for AS and 2 - 439 nM for MFQ. According to dormancy assays, schizonts were observed in the P. falciparum reference isolate NF54 and in the clinical isolate S-01/15 after pressure with 62.5 nM, 250 nM and 1,000 nM DHA. The recovery period ranged from 4 to 40 days. For LMF was observed the growth to the schizont stage in NF54, in the days 7 e 12 after exposure to 66.6 nM and 200 nM of the drug, respectively. Schizonts were seen in the P. falciparum clinical isolate FS-08/15 after pressure with 100 nM of AS, right after incubation period, with no dormancy of trophozoites. In flow cytometry assays, viable young trophozoites of P. falciparum labeled with DAPI and Rhodamine 123 were observed at the maximum concentrations of DHA (1,000 nM) and LMF (200 nM). Finally in RSA, the growth rate (GR) and percentage of survival (PS) of the reference isolate was 2.92 and 4.19%, respectively, after pressure with 700 nM of DHA. The same isolate pressed with 3,500 nM of LMF presented GR of 3.6% and PS of 2.25%. In conclusion, microscopic evaluation of ex vivo and in vitro sensitivity tests underestimates the P. falciparum response to artemisinin-based combination therapy (ACT). Our results suggest that the dormancy, main mechanism of tolerance to artemisinin (ART), is not presented in all clinical isolates of P. falciparum. Flow cytometry was able to confirm the parasite viability accurately. In this study, for the first time the dormancy of P. falciparum after pressure with LMF was reported

A malária apresenta um alto índice de mortalidade com mais de 500 mil mortes registradas em 2013. Para agravar a situação de saúde pública, foi descrito o surgimento de resistência às drogas usadas na terapêutica da doença. Torna-se necessário a identificação e o estudo de novos alvos antimaláricos. A via MEP se mostra como um potencial alvo para o desenvolvimento de drogas contra P. falciparum uma vez que está ausente em humanos. Nossos objetivos foram avaliar a função da vitamina E biossintetizada pelo parasita, caracterizar a biossíntese de vitamina K1 e o metabolismo de fitol. Esse estudo determinou que a vitamina E biossintetizada pelo parasita atua no sistema redox do parasita. Por outro lado, mostramos que a biossíntese de vitamina K1 é ativa no parasita e detectamos sua forma reduzida. Por fim, observamos que existe uma via de reaproveitamento de fitol em P. falciparum assim como em plantas. O estudo abre oportunidades para um desenvolvimento racional de novos antimaláricos e aprofunda o conhecimento na biologia do parasita. / Malaria has the highest mortality rate with more than 500 000 deaths in 2013. The public health situation gets worse because it has been described the emergence of resistance to common drugs used in the treatment of disease. It is necessary to identify and study of new antimalarial targets. The MEP pathway is a potential target for drug development against Plasmodium falciparum once it is absent in humans. Our objectives were to evaluate the function of vitamin E biosynthesized by the parasite and characterize the biosynthesis of vitamin K1 and the phytol metabolism. This study determined that vitamin E biosynthesized by the parasite operates in the redox system of the parasite. We show the biosynthesis of vitamin K1 is active on parasite and we detected its reduced form. Finally, we demonstrate that there is a phytol salvage pathway in P. falciparum as well as plants. The study opens opportunities for the rational development of new antimalarials and deepens knowledge on parasite biology.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 4 uppsatser.

La forme la plus sévère de paludisme est causée par le parasite unicellulaire P. falciparum. Lors de la phase intra-érythrocytaire de son développement, P. falciparum met en place des fonctions métaboliques nécessaires à son développement dans l'érythrocyte, à sa multiplication et enfin à sa dissémination vers d'autres érythrocytes. Comprendre et élucider les structures et les dynamiques du réseau métabolique chez le parasite, permettent de découvrir de nouvelles voies métaboliques et des étapes clefs qui peuvent jouer un rôle important dans le développement du parasite. Elles permettent également de déterminer le mécanisme d'action des agents antipaludiques et de mieux comprendre les résistances associées aux traitements existants. Dans cet objectif, une approche métabolomique ciblée, utilisant la chromatographie liquide couplée à la spectrométrie de masse en tandem (LC-MS/MS) a été utilisée. Cette approche consiste en une quantification absolue de métabolites impliqués dans les voies de biosynthèse des phospholipides membranaires du parasite mais également d'autres métabolites qui reflètent son statut métabolique. Nous avons dans un premier temps, déterminé les distributions et les quantités absolues des métabolites présents dans un érythrocyte infecté par P. falciparum en comparaison avec un érythrocyte sain. Nous avons également mis en évidence les perturbations causées par cette infection sur le métabolisme de l'érythrocyte humain ainsi que les différents échanges qu'entretien le parasite avec sa cellule hôte mais également avec le milieu extracellulaire. Le métabolisme phospholipidique de Plasmodium est complexe car il possède plusieurs voies de synthèses opérant à partir de précurseurs initiaux distincts et conduisant à la synthèse d'un même produit final. Dans l'objectif d'étudier la contribution relative des différentes voies métaboliques dans la biosynthèse des phospholipides majoritaires chez P. falciparum (PC et PE), nous avons développé une approche qui consiste à incuber les érythrocytes infectés en présence de précurseurs marqués. / The most severe form of malaria is caused by the single-celled parasite P. falciparum. During the intra-erythrocytic stage of its development, P. falciparum implements several metabolic functions necessary for its development in the erythrocyte, its multiplication and finally to its spread to other erythrocytes. Understand and elucidate the structures and the dynamics of the parasite's metabolic network is useful to discover new metabolic pathways and key steps that may play an important role in the development of the parasite. They also help determine the mechanism of action of antimalarial agents and better understand the resistances associated with available treatments. For this purpose, a targeted metabolomics approach, using liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used. This approach consists of an absolute quantitation of metabolites involved in the biosynthesis of membrane phospholipids of the parasite but also other metabolites that reflect its metabolic status. We initially determined the distributions and the absolute amounts of metabolites in infected erythrocytes in comparison with healthy erythrocytes. We also highlighted the disruption caused by this infection on the metabolism of the human erythrocyte and the various interactions between the parasite and its host cell as well as the extracellular medium. The phospholipids metabolism of Plasmodium is complex because it has several synthetic pathways operating from separate initial precursor and leading to the synthesis of a single end product. With the aim to study the relative contribution of these different metabolics pathways in the biosynthesis of the most important phospholipids in P. falciparum (PC and PE), we have developed an approach that involves incubation of infected erythrocytes in the presence of labeled precursors.

Um importante fator de patogenicidade de P. falciparum, causador da malária, é a presença de antígenos altamente polimórficos, codificados por famílias multigênicas como var e rif. O grande polimorfismo destes genes em isolados de diferentes regiões contrasta com o fato de existirem, em diferentes isolados de campo brasileiros, alelos conservados. Respostas humorais contra estas proteínas são consideradas importantes na aquisição de proteção contra os sintomas da doença em regiões endêmicas. Portanto, medimos a resposta humoral contra antígenos recombinantes PfEMP1 e RIFIN e detectamos níveis baixos de resposta tanto em indivíduos sintomáticos quanto em indivíduos assintomáticos infectados pelo parasita. Estas respostas foram baixas quando comparadas às respostas contra MSP119 da superfície do merozoíta e parecem ser de curta duração. Com base nestes resultados, as respostas contra domínios DBLa, em situações hipoendêmicas, parecem ocorrer em função da presença do parasita circulante, e não são relacionadas à proteção contra os sintomas clínicos da doença. / An important factor in the pathogenicity of P. falciparum, the causing agent of malaria is the expression of highly polymorphic antigens encoded by the multigene families var and rif. The extreme polymorphism of these genes in strains from different geographical regions is in contrast with the observation of a number of conserved alleles found in Amazonian isolates. The humoral response against these proteins is considered an important factor in the immunity against symptomatic infection in áreas with high transmission. We measured the antibody response against recombinant PfEMP1 and RIFIN antigens and detected low responsiveness of symptomatic and asymptomatic malaria infected individuals. These responses were not only weak when compared to the anti-merozoite surface protein 1 response, but also ceased rapidly after the removal of circulating parasites. On the basis of these results, the response against DBLa seems to be dependent on the presence of parasites and not important for the observed protection against symptomatic infection in hypoendemic settings.

Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2015-05-18T10:58:40Z No. of bitstreams: 2 license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Tese - Lourival de Almeida Silva - 2015.pdf: 2573495 bytes, checksum: 0eee1e3d91463a3f757ecdc4fe7126ce (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2015-05-18T11:02:27Z (GMT) No. of bitstreams: 2 license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Tese - Lourival de Almeida Silva - 2015.pdf: 2573495 bytes, checksum: 0eee1e3d91463a3f757ecdc4fe7126ce (MD5) / Made available in DSpace on 2015-05-18T11:02:27Z (GMT). No. of bitstreams: 2 license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Tese - Lourival de Almeida Silva - 2015.pdf: 2573495 bytes, checksum: 0eee1e3d91463a3f757ecdc4fe7126ce (MD5) Previous issue date: 2015-02-27 / Leishmaniasis is a neglected tropical disease responsible for physical, economic and social damages. Even though malaria is not classified as a neglected tropical disease, is responsible for high morbidity and mortality, especially in African countries. Current treatments for both diseases face several drawbacks, including the evolution of drugresistant parasites, the high cost of major drugs and the high toxicity of others. For these reasons, there is an urgent need to develop new drugs that minimize these downsides and, consequently, help eradicate these diseases. To overcome these difficulties, both academics and pharmaceutical companies are increasingly employing the so-called “drug repositioning strategy”. Drug repositioning aims to find new applications for drugs approved for other indications, and has proven valuable for decreasing research costs as well as to decrease the time required to market the "new" drug. In the present study, we used bioinformatics to identify and analyze molecular targets of the energy metabolism of Leishmania spp and of the P. falciparum apicoplast. The energy metabolism of Leishmania and the apicoplast metabolism have various enzymes that can be targeted by specific drugs, leading to lower toxicity and more promising therapies for humans. Using the TDR Targets database, we were able to identify 94 genes and 93 Leishmania energy metabolism targets. We identified 44 positive targets in these databases, and for 11 of these targets we found drugs already approved for use in humans. We used a similar strategy to identify antimalarial drugs that acted specifically against the apicoplast metabolism. The GeneDB database of the P. falciparum genome was used to compile a list of 600 proteins with apicoplast signal peptides. Each of these proteins was treated as a potential drug target and its predicted sequence was used to interrogate three different open access databases (DB TTD, DrugBank and STITCH ). We identified many drugs with the potential to interact with 47 peptides allegedly involved in apicoplast biology in P. falciparum. Fifteen of these hypothetical targets are predicted to interact with drugs are already approved for clinical use, but were never evaluated against malaria parasites. Our results suggest that the drugs identified here show potential activity against leishmania parasite and malaria, but need experimental validation to confirm their effectiveness. / As leishmanioses são parasitoses negligenciadas responsáveis por prejuízos físicos, econômicos e sociais. A malária, embora não seja classificada como negligenciada, é responsável por altos índices de morbidade e mortalidade, principalmente nos países africanos. Ao longo dos anos, o tratamento dos infectados tem sido a forma mais eficaz de controle dessas endemias. Entretanto, os efeitos tóxicos, o alto custo dos fármacos e a resistência dos parasitos têm sido os maiores desafios enfrentados pela terapêutica das leishmanioses e da malária. Sendo assim, é urgente a necessidade de desenvolver novos fármacos que minimizem esses transtornos e contribuam para erradicação dessas parasitoses. Diante disso, laboratórios acadêmicos, governos e organizações não governamentais têm apoiado projetos voltados para o reposicionamento de fármacos aprovados com vistas a reduzir custos e tempo de produção de novos antiparasitários. No presente trabalho, utilizamos a bioinformática para identificar, buscar e analisar alvos moleculares do metabolismo energético de Leishmania spp e do apicoplasto de P. falciparum, visando o reposicionamento in silico de fármacos. Utilizando a base de dados TDR Targets, identificamos 94 genes e 93 alvos do metabolismo energético de Leishmania. Em seguida, utilizando a sequência peptídica de cada alvo, interrogamos as bases de dados Drug Bank e TTD na busca de fármacos. Nossa busca resultou em 44 alvos positivos, dos quais 11 interagiam com 15 fármacos aprovados para uso em humanos. Utilizamos estratégia semelhante para identificar fármacos antimaláricos que atuassem especificamente contra o metabolismo do apicoplasto. A base de dados GeneDB do genoma de P. falciparum foi usada para compilar uma lista de cerca de 600 proteínas com peptídeos sinais do apicoplasto. Cada uma dessas proteínas foi tratada como potencial alvo de fármaco e sua sequência prevista foi usada para interrogar três diferentes bases de dados de acesso livre (TT DB, DrugBank e STITCH ) Identificamos fármacos com potencial de interagir com 47 peptídeos supostamente envolvidos na biologia do apicoplasto do P. falciparum. Quinze desses alvos hipotéticos são previstos interagir com fármacos já aprovados para uso clínico, mas que nunca foram avaliados contra os parasitos da malária. Os nossos resultados sugerem que os fármacos aqui identificados apresentam potencial para tratamentos das leishmanioses e da malária, mas que necessitam de validação experimental para confirmar sua eficácia.

Submitted by Erika Demachki (erikademachki@gmail.com) on 2015-10-23T17:15:13Z No. of bitstreams: 2 Dissertação - Karlla Gonçalves Macedo - 2014.pdf: 3559333 bytes, checksum: be77b4325f787c0048a0c9a15e8c800b (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Erika Demachki (erikademachki@gmail.com) on 2015-10-23T17:16:49Z (GMT) No. of bitstreams: 2 Dissertação - Karlla Gonçalves Macedo - 2014.pdf: 3559333 bytes, checksum: be77b4325f787c0048a0c9a15e8c800b (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2015-10-23T17:16:49Z (GMT). No. of bitstreams: 2 Dissertação - Karlla Gonçalves Macedo - 2014.pdf: 3559333 bytes, checksum: be77b4325f787c0048a0c9a15e8c800b (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2014-08-05 / Drug discovery and development process requires high investments of both time and money. Strategies for drug design aided by computers, CADD (Computer-Aided Drug Design) have gained prominence over the last decades, in order to minimize the impact of those costs. CADD techniques also allow the exploration of a greater number of biological targets and promising molecules. Malaria is an endemic disease in Africa and in South American caused by the protozoa of the genus Plasmodium. In 2012, 207 million cases and 627,000 deaths were estimated, according to the World Health Organization. The enzyme dihydroorotate dehydrogenase (DHODH) catalyzes the fourth step of the pyrimidine biosynthesis, and consists in a validated target for the design of new antimalarial agents. The aim of this study was to develop structure-activity relationships (SAR) rules and to generate quantitative structure-activity relationships (QSAR) models using a set of triazolopyrimidines described in the literature as inhibitors of DHODH from P. falciparum (PfDHODH). SAR rules were established using methods of clustering, activity cliffs and activity landscapes. In addition, several models of 2D-QSAR and hologram QSAR (HQSAR) were developed and validated. The SAR analyses allowed the understanding of the basic structural requirements for the antimalarial activity of triazolopyrimidines, like alkyl halides substituents on the triazolopimidinic ring, hydrophobic substituents in the para position on the benzene ring, all in agreement with the chemical space inside the active site of the PfDHODH. The HQSAR and 2D-QSAR models showed good statistical parameters and good predictive ability. The HQSAR contour maps were also consistent with the chemical space of the active site of the enzyme. The results of this study could serve as guide for the design of new antimalarials with higher potency. / O processo de planejamento e desenvolvimento de novos fármacos é um trabalho complexo, que demanda elevados investimentos de tempo e dinheiro. Estratégias de planejamento de fármacos auxiliadas por computador, CADD (Computer-Aided Drug Design) vêm se destacando, pois minimizam gastos e tempo, além de poder explorar um número maior de alvos biológicos e moléculas promissoras. A malária é uma doença endêmica grave na África e América do Sul, causada por protozoários do gênero Plasmodium. Em 2012 foram estimados 207 milhões de casos e 627.000 mortes, de acordo com a Organização Mundial da Saúde. A enzima diidroorotato desidrogenase (DHODH) atua na quarta etapa da biossíntese de pirimidinas, é um alvo validado para o planejamento de novos agentes antimaláricos. O objetivo geral deste trabalho foi desenvolver regras de relação entre estrutura e atividade (SAR) e modelos robustos e preditivos de relações quantitativas entre estrutura e atividade bidimensionais (QSAR-2D), utilizando um conjunto de triazolopirimidinas descritas na literatura como inibidores da DHODH de P. falciparum (PfDHODH). Foram desenvolvidas regras de SAR utilizando os métodos de análise de agrupamentos, cliffs de atividade e landscapes de atividade. Além disso, desenvolveu-se e validou-se vários modelos de QSAR–2D e de holograma QSAR (HQSAR). As análises de SAR, permitiram estabelecer requisitos estruturais essenciais para a atividade antimalárica das triazolopirimidinas, como substituintes haletos de alquila no anel triazolopimidínico, substituintes hidrofóbicos na posição para no anel benzênico, todos de acordo com o espaço químico da cavidade de interação da PfDHODH. Os modelos de HQSAR e QSAR-2D apresentaram bons parâmetros estatísticos e boa capacidade preditiva. Os mapas de contribuição de HQSAR também estão de acordo com o espaço químico da cavidade de interação da PfDHODH. Os dados obtidos servem como guia para o planejamento de novos antimaláricos com maior potência.

Pour assurer ses besoins de croissance, multiplication, et survie, Plasmodium modifie sa cellule hôte, l'érythrocyte, après l'invasion. Le parasite met en place ainsi un système d'échanges (import/export) avec sa cellule hôte et le milieu extérieur. Nous avons identifié dans la base de données de Plasmodium berghei, le parasite de rongeurs, une famille de gènes, sep, correspondant à la famille etramp chez Plasmodium falciparum. Cette famille de gènes code pour des petites protéines exportées, et conservées dans tout le genre Plasmodium. Les protéines SEP (13?16 kDa) contiennent en N-terminal un peptide signal prédit, un domaine hydrophobe interne, et elles diffèrent au niveau des régions C-terminal et 3' UTR. Toutefois, les protéines SEP sont exprimées à différents moments du cycle de Plasmodium. Durant le cycle érythrocytaire, PbSEP1 et PbSEP3 sont exprimées à partir du stade trophozoïte, et la même quantité de protéine est détectée au stade schizonte et gamétocyte, pendant que PbSEP3 est hautement détectée dans les trophozoïtes mûrs et les gamétocytes. Chez le moustique, PbSEP1 et PbSEP3 sont détectées seulement chez les ookinètes, alors que PbSEP2 est très abondante dans les ookinètes, oocystes, et sporozoïtes des glandes salivaires. Les protéines SEP ont également des localisations différentes. Dans l'érythrocyte, PbSEP1 est localisée dans la membrane de la vacuole parasitophore, alors que PbSEP2 et PbSEP3 sont exportées au-delà de cette vacuole, et sont ainsi localisées dans la cellule hôte, en association avec des structures vésiculaires. Dans cette étude, nous avons identifié les signaux d'adressage des protéines SEP dans la vacuole parasitophore et dans la cellule hôte, chez Plasmodium berghei. L'autre partie du travail, effectuée à l'Université de Montpellier II, a consisté à étudier la localisation de deux protéines du squelette sous- membranaire de l'érythrocyte, la dématine, et l'adducine, durant le développement intra-érythrocytaire de Plasmodium falciparum. Le but de cette étude étant d'identifier un mécanisme potentiel d'internalisation des composants du squelette sous-membranaire de l'érythrocyte dans le parasite. Des études d'immuno-localisation ont montré que la dématine et l'adducine sont internalisées à partir du stade trophozoïte, et sont localisées probablement à la vacuole parasitophore (membrane et/ou lumière). Cette internalisation a été confirmée par des études de fractionnement cellulaire et d'accessibilité à la protéinase K, montrant que la dématine est totalement internalisée, alors l'adducine ne l'est que partiellement, suggérant une localisation de la protéine à la périphérie du parasite. / Plasmodium endurance depends on the ability of the parasite to reorganize the cytosol of the erythrocyte, a terminally differentiated cell, and remodel its skeleton membrane immediately after invasion. In this way the parasite can organize the import/export of the molecules necessary to its survival. The comprehension of cellular trafficking mechanisms which occur during Plasmodium infection is a very important step and fundamental contribute to understand the biology of the malaria parasite.We identified in database of the rodent malaria parasite Plasmodium berghei the gene family sep, corresponding to etramp in P. falciparum, encoding small exported proteins conserved in the genus Plasmodium. SEP proteins (13?16 kDa) contain a predicted signal peptide at the NH2-terminus, an internal hydrophobic region while they differ in their C-terminal region; the genes share the upstream regulative region while differ in the 3' UTR. Despite this, we showed that SEPs have a different timing of expression and a different localization: in the erythrocytic cycle PbSEP1 and PbSEP3 start to be expressed at trophozoite and the same amount of protein is detected also in schizonts and gametocytes, while PbSEP2 is highly detected in mature trophozoites and even more in gametocytes. In mosquitoes stages PbSEP1 and PbSEP3 are expressed only in ookinetes, while PbSEP2 is very abundant in ookinetes, oocysts and in sporozoites of the salivary glands. SEPs also have a different localization in the iRBC: PbSEP1 is targeted to the membrane of the parasitophorous vacuole, while PbSEP2 and 3 are exported beyond the parasite membrane and translocated to the host cell compartment in association with vesicle-like structures. In this study we identified the specific signals necessary for the correct timing of expression and to direct SEP proteins to the vacuolar membrane and to the host cell compartments.The second part of the work was carried out in Montpellier II University and aims to identify the localization of two RBC membrane skeleton components, dematin and adducin, during Plasmodium falciparum infection. Our purpose is to recognize a possible mechanism of internalization of host cytoskeleton components to the parasite compartments. In fact, IFA experiments carried on iRBCs showed that dematin and adducin start to be internalized at trophozoite stage and localize at the periphery of the parasite, most probably at the parasitophoruos vacuole (PV) membrane/lumen. Dematin and adducin internalization during Plasmodium infection is also demonstrated by subcellular fractionation and proteinase K assay: while dematin is fully internalized, adducin is partially protected and suggesting a localization of the protein at the periphery of the parasite where it can be exposed to PK degradation.

La doxycycline est l’une des molécules recommandées par l’OMS en prophylaxie pour les voyageurs dans les zones d’endémie palustre, en particulier dans les zones de multirésistance. Une étude récente avait suggéré que les isolats de P. falciparum présentaient différents niveaux de sensibilité à la doxycycline et que l’augmentation du nombre de copies de deux gènes, pfmdt ou pftetQ, pouvait être associée à une baisse de sensibilité.Le premier objectif de ce travail a consisté à valider ce modèle à partir d’un nouvel échantillonnage d’isolats africains. Le second objectif était d’évaluer le nombre de copies de ces deux gènes sur des isolats originaires de Thaïlande. Le troisième objectif a consisté à rechercher d’autres sources de résistance en investiguant le polymorphisme des gènes codant l’ARN ribosomal plasmodial potentiellement impliqués dans la résistance in vitro à la doxycycline.Les résultats nous ont permis de confirmer que le nombre de copies des gènes pfmdt ou pftetQ pouvait être impliqué dans la résistance in vitro à la doxycycline en Afrique. Les résultats concernant les isolats Thaï n’ont pas permis de corréler le nombre de copies des gènes pfmdt et pftetQ au phénotype CI50. Ces éléments montrent que ce mécanisme de résistance seul est insuffisant pour expliquer la résistance à la doxycycline ; les résultats sont en faveur d’une résistance médiée par plusieurs gènes.La recherche de points de mutation sur le gène pfssrRNA codant pour la petite sous-unité ribosomale de l’ADN plasmodial n’a pas abouti. D’autres cibles moléculaires sont en cours d’étude pour expliquer les mécanismes de résistance de P. falciparum à la doxycycline. / Doxycycline is currently one of the recommended chemoprophylactic regimens for travellers visiting malaria-endemic, particularly in countries with a high prevalence of resistance to chloroquine and multiresistance. A previous study suggested that increased pfmdt or pftetQ copy number could be associated with a lower susceptibility to doxycycline.The first aim of this study was to validate the pre-established model involving these two molecular markers with other African isolates. The second was to evaluate these markers in P. falciparum isolates coming from a multiresistance area in Thaïland. The third was to investigate the eventual association between the polymorphism in genes encoding ribosomal rRNA and in vitro resistance to doxycycline.The results confirm that pfmdt or pftetQ copy numbers should be involved in in vitro susceptibility to doxycycline in African P. falciparum isolates. The results concerning the Thai isolates indicate that there is no correlation between the pfmdt and pftetQ genes copy numbers and the belonging to the high doxycycline IC50 phenotype; this implies that this mechanism of resistance is not enough by itself to explain resistance to doxycycline; it augurs that the resistance to doxycycline should be controlled by multiple genes, and that these genetic markers could be continent-dependent. The search for points of mutation in isolates from the different doxycycline IC50 phenotypic groups has not resulted with pfssrRNA. Other therapeutic targets are being considered to explain P. falciparum resistance to doxycycline.

Les phosphoantigènes (P-Ag) de P. falciparum (P.f.) induisent une forte activation et une expansion des lymphocytes T (LT) Vγ9Vδ2 par un mécanisme encore mal décrit. Les LT Vγ9Vδ2 actives inhibent le cycle sanguin de P. f. par des médiateurs cytotoxiques solubles, inhibant ainsi la capacité invasive des mérozoites. Il a été montre in vitro que des LT Vγ9Vδ2 activés par les P-Ag peuvent présenter des antigènes et activer les LT αβ, agissant ainsi comme des cellules présentatrices d’antigènes (APC). Cette fonction n’a cependant pas été démontrée dans un contexte physiopathologique. Le but de ce projet est i) d’étudier les mécanismes d’activation des LT Vγ9Vδ2 par les stades sanguins P. f. et ii) d’evaluer le potentiel APC des LT Vγ9Vδ2 stimules par P. f. Nous montrons que l’activation des LT Vγ9Vδ2 par des globules rouges parasites par P. f. (GRP) intacts ne dépend ni d’un contact cellulaire, ni de l’expression de butyrophiline par le GRP. Les LT Vγ9Vδ2 sont activés par des molécules contenues dans les surnageants de culture de GRP, ayant les caractéristiques de P-Ags et étant libérées lors de la rupture des GRP. In vitro, les LT Vγ9Vδ2 stimules par les GRP expriment des marqueurs de surface associés à un rôle d’APC et cross-présentent un antigène modèle à une lignée T CD8 spécifique. In vivo, nous montrons une expression augmentée des marqueurs APC à la surface de LT Vγ9Vδ2 de patients infectés par P. falciparum. L’ensemble de ces données suggèrent que les P-Ag libérés par les GRP dans le milieu extracellulaire pourraient activer les LT Vγ9Vδ2 à distance, et ouvrent de nouvelles perspectives quant au rôle des LT Vγ9Vδ2 dans la réponse immunitaire adaptative anti-palustre. / P. falciparum derived phosphoantigens (P‐Ag) induce potent activation and expansion of Vγ9Vδ2 T-cells by a poorly described mechanism. Activated Vγ9Vδ2 T cells inhibit the Plasmodium falciparum blood cycle through soluble cytotoxic mediators, abrogating merozoite invasion capacity. In vitro, P-Ag activated Vγ9Vδ2 T lymphocytes have been shown to present antigens and induce αβ T lymphocyte responses, i.e. to act as an antigen presenting cell (APC). Whether this activity can be involved in a pathophysiological context is unknown. The aim of this PhD project is to a) investigate the mechanisms of Vγ9Vδ2 T cell activation by blood stage P. falciparum and b) assess the potential of P. falciparum activated Vγ9Vδ2 T cells to display APC functionality. We show that Vγ9Vδ2 T-cell activation by intact iRBCs is independent of iRBC contact and butyrophilin expression. Blood stage culture supernatants can potently activate Vγ9Vδ2 T-cells and bioactivity is found to be attributable to P-Ags released at the time of parasite egress from the RBC. In vitro iRBC stimulated Vγ9Vδ2 T cells up-regulate surface expression of APC associated markers and can cross-present a model antigen to specific CD8 T cell responders. In vivo we demonstrate an increase in surface expression of APC makers on Vγ9Vδ2 T cells from P. falciparum infected patients.Altogether, these data outline a framework whereby P‐Ag release by iRBC into extracellular milieu can promote activation of distant Vγ9Vδ2 T cells, and opens the door to a new aspect of Vγ9Vδ2 T cell contribution to P. falciparum adaptive immune responses.